Please login to the form below

Not currently logged in
Email:
Password:

PharmaLex announces joint venture with Vintura

Partnership provides benefits for both organisations

PharmaLex

PharmaLex has entered into a joint venture with life sciences and healthcare strategic consultancy Vintura. 

The partnership will provide benefits for both organisations – Vintura will be able to access the expertise offered by PharmaLex's global reach in 31 offices across 17 countries, and PharmaLex is set to build on its service portfolio offering to clients with Vintura’s specialisms.

The two organisations will continue to operate under their respective, well-established brands.

"We are very excited to be joining forces with the PharmaLex Group," said Gérard Klop, partner at Vintura.

"PharmaLex has a very strong heritage in the life sciences sector and we see clear synergies between our two organisations. In addition, the international footprint of PharmaLex supports our international growth objectives," he added.

PharmaLex is a specialist service provider for the pharmaceutical industry, offering services for development consulting, regulatory affairs, quality management & compliance and pharmacovigilance.

Vintura is a strategy and organisation consultancy with speciality in healthcare and life sciences, and has offices based in Amsterdam, the Netherlands and Munich, Germany.

9th December 2019

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics